Salute e Benessere
TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as hydrochloride monohydrate), administered orally. Patients should be cautioned about the heightened risk of severe or fatal interstitial lung disease/pneumonitis, liver toxicity, and potential embryo-fetal toxicity, necessitating effective contraception during and shortly after treatment.
Tepotinib specifically targets MET, including variants with exon 14 skipping mutations. It blocks HGF-dependent and independent MET phosphorylation, disrupting MET-driven signaling pathways. Additionally, at clinically relevant concentrations, Tepotinib inhibits melatonin 2 and imidazoline 1 receptors. In vitro studies show that it suppresses tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent cancer cells. In mouse models with MET-driven tumors, including those with MET exon 14 skipping alterations, Tepotinib reduced tumor growth, sustained MET phosphorylation inhibition, and, in one case, decreased metastasis formation.
The recommended dose of TEPMETKO is 450 mg taken orally once daily until disease progression or intolerable toxicity occurs. Patients should take it at the same time each day, swallowing tablets whole without chewing, crushing, or splitting them. If a dose is missed and less than eight hours remain until the next scheduled dose, patients should skip it. In cases of vomiting after taking TEPMETKO, the next dose should be taken at the usual time.
JP: 2020
Learn more about TEPMETKO projected market size for NSCLC @
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 81% of all diagnosed cases. Early detection greatly improves outcomes, but diagnosing NSCLC and other lung cancers is challenging because their symptoms are often mistaken for common illnesses or the long-term effects of smoking. Consequently, of NSCLC cases are already at advanced stages by the time they are identified, making treatment more difficult. Around of EGFR mutations in NSCLC involve either exon 19 deletions or the exon 21 L858R substitution, both of which are classified as sensitizing mutations.
Until the last decade, chemotherapy was the primary treatment for advanced and metastatic lung cancer. However, this changed in 2015 with the approval of the first immune checkpoint inhibitor (ICI), (pembrolizumab), as a second-line therapy for advanced cases. This was followed by (atezolizumab) in 2016. Both therapies were later approved for first-line treatment, broadening their use to a larger patient population. In 2020, the combination of (nivolumab) and ipilimumab also received approval as a first-line treatment for metastatic NSCLC.
According to DelveInsight, the NSCLC market size across the 7MM is projected to grow from in 2024, with a substantial CAGR through 2034. This growth is largely driven by the introduction of emerging therapies during the forecast period (2025–2034).
Discover more about the NSCLC market in detail @
The NSCLC pipeline is very robust with the promising therapies such as (AbbVie), (Daiichi Sankyo/AstraZeneca), (Daiichi Sankyo/AstraZeneca), (Immutep), (acasunlimab) (Genmab), (Moderna Therapeutics/Merck), (BeyondSpring), (Eli Lilly and Company), (Cullinan Oncology/Taiho Pharma), (AstraZeneca), (OSE Immuno-therapeutics), (Pfizer), (ImmunityBio), (Jiangsu Hansoh Pharmaceutical), (GSK), (AstraZeneca/Hutchison MediPharma), (Gilead Sciences), (Jiangsu HengRui Medicine), (BieGene), (AstraZeneca), (OncoC4/BioNTech), (Akeso Biopharma/Summit Therapeutics), (Incyte/Macrogenics), (Roche/Genentech), (Roche), (Merck and Kelun-Biotech), (GSK and AnaptysBio), (Boehringer Ingelheim), (Bayer), (Shanghai Henlius Biotech), (AstraZeneca), (Merck, Taiho Pharmaceutical, and Astex), (Arcus Biosciences and Gilead Sciences), (nivolumab and relatlimab) (Bristol-Myers Squibb), (iTeos Therapeutics and GSK), (ArriVent BioPharma), (Dizal Pharmaceutical), (GSK), (AbbVie), (Regeneron Pharmaceuticals), (Biotheus/BioNTech), (Hansoh BioMedical), (IO Biotech), (NeoTX Therapeutics/Active Biotech), (FUJIFILM Corporation), (BioNTechSE/Regeneron Pharmaceuticals), (Candel Therapeutics), (BioAtla), (BerGenBio/Rigel Pharmaceuticals), (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku), (Iovance Biotherapeutics), (Innovent Biologics), (Alethia Biotherapeutics), (Verastem Oncology), (Apollomics), (Lantern Pharma), (Johnson & Johnson Innovative Medicine), (Amgen), (Sutro Biopharma), (Prelude Therapeutics), (Seagen), (Astellas Pharma), (Replimune), (Seagen), (Jazz Pharmaceuticals), (Beijing Biostar Pharmaceuticals), (Regeneron Pharmaceuticals), (SignalChem Lifesciences), (GenFleet), (Regeneron Pharmaceuticals), (Taiho Oncology), (RedCloud Bio), (J INTS BIO), (Forward Pharma), (AZD7789) (AstraZeneca), (Pfizer), (Galecto Biotech), (Healthcare/Taiho Pharmaceutical), (Ellipses Pharma/Kelun-Biotech), (Merus), (Nuvalent), (Nuvalent), (Revolution Medicines), (Genprex), (PDC*line Pharma), (BioAtla and BeiGene), (Promontory Therapeutics), (Monte Rosa Therapeutics), (GAIA BioMedicine), (Traws Pharma), (Hummingbird Bioscience), (Avistone Biotechnology), (Avistone Biotechnology), (Mythic Therapeutics), (Sichuan Kelun-Biotech Bio-pharmaceutical), (Ribon Therapeutics), (Kiromic BioPharma), (Kairos Pharma), (MediLink Therapeutics), and others.
To know more about the number of competing drugs in development, visit @
Discover how TEPMETKO is shaping the NSCLC treatment landscape @
TEPMETKO competes in a growing but highly specialized market where MET-targeted therapies are gaining traction due to their . The market for MET inhibitors is expanding as precision oncology advances and molecular diagnostics become more widely available, who would benefit from targeted treatments like TEPMETKO.
A key factor shaping TEPMETKO's market dynamics is competition. It directly competes with , another MET inhibitor approved for the same indication. While TEPMETKO offers the advantage of compared to TABRECTA's , both drugs have similar efficacy profiles, making physician and patient preference an important differentiator. Additionally, and combination therapies in clinical trials could impact TEPMETKO's long-term market position.
Regulatory approvals and market access play a crucial role in TEPMETKO's adoption. The drug has been approved in multiple regions, including the U.S., Europe , and Japan , but vary by market. Payer policies, along with the of MET inhibitors compared to other targeted therapies, influence prescription trends. Furthermore, will be critical in demonstrating TEPMETKO's sustained effectiveness and safety, which could support expanded indications and increased market penetration.
Looking ahead, the MET inhibitor market is expected to grow with advances in biomarker-driven therapy, further refining patient selection. TEPMETKO's success will depend on to strengthen its competitive edge. As new entrants emerge, Merck KGaA's ability to differentiate TEPMETKO through combination strategies or enhanced formulations may determine its long-term sustainability in this evolving landscape.
Dive deeper to get more insight into TEPMETKO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key C-MET mNSCLC companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key C-MET non-small cell lung cancer companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
View original content: https://www.prnewswire.co.uk/news-releases/tepmetko-continues-to-strengthens-its-position-as-a-leading-metex14-skipping-nsclc-therapy--delveinsight-302394100.html